CMA drops probe into Merck’s Remicade discounts
The UK’s antitrust enforcer has closed its abuse of dominance investigation into Merck Sharp & Dohme’s discount scheme, despite finding no “procompetitive rationale or efficiency justification” for the conduct.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.